Application
CD40-TRAF6 signaling inhibitor has been used to treat human embryonic kidney (HEK)-293T cellsto test its inhibitory effect on the tumor necrosis factor receptor (TNFR)-associated factor 6 (TRAF6) leading to subsequent abrogation of (P2RY6)-dependent nuclear factor kappa B (NF-κB).
Biochem/physiol Actions
CD40-TRAF6 signaling inhibitor is a small molecule that binds to TRAF6, blocking interactions with CD40. The compound inhibits CD40-induced production of IL-1b and IL-6 in primary macrophages. The compound reduces insulin resistance and adipose tissue inflammation in a mouse diet induced obesity model.
CD40-TRAF6 (cluster of differentiation 40-TNF receptor associated factor) signaling is recognized as an effective target in treating vascular disease.
Packaging
5, 25 mg in glass bottle
This product has met the following criteria to qualify for the following awards: